Open access

Introductory Chapter: Urinary Tract Infections (UTIs)

Written By

Wael Hegazy

Submitted: 26 April 2023 Published: 02 November 2023

DOI: 10.5772/intechopen.111783

From the Edited Volume

Urinary Tract Infections - New Insights

Edited by Wael Hegazy

Chapter metrics overview

55 Chapter Downloads

View Full Metrics

1. Introduction

Urinary tract infections (UTIs) are a prevalent bacterial infection in humans, accounting for about 40% of all hospital-acquired infections [1, 2]. The occurrence of UTIs has increased by 60% in the last three decades between 1990 and 2019, highlighting the significant public health issue they pose [3]. The UTIs symptoms commonly include bacteriuria along with suprapubic discomfort, urgency, urinary frequency, and dysuria [4]. UTIs are classified into two types: uncomplicated UTIs, also known as cystitis, affect only the bladder and can be resolved with simple antibiotic treatments. While the disseminated infections to the upper urinary tract are referred as complicated UTIs, that require more aggressive antibiotic treatments for longer periods. Furthermore, complicated UTIs are associated with higher rates of sepsis, recurrent infection, treatment failure, and significant morbidity and mortality [4, 5, 6, 7]. Uncomplicated UTIs affect 40–60% of females, at least once in their lifetime, on the other hand, all UTIs in males are usually considered complicated [8, 9, 10]. Recurrent UTIs are characterized by the occurrence of at least two acute UTI episodes within a span of 10 months or three episodes within a 12-month period, with a higher incidence in females than males [11, 12]. The UTIs can be self-infected, community-acquired, or nosocomial. Community-acquired infections typically result from low sanitary precautions, poor personal hygiene, or multiple sexual partners [7, 11]. The risk of self-infections often occurs in immunocompromised individuals as commensal inhabitants from the periurethral, vaginal, or rectal flora usually cause it [13, 14].

Advertisement

2. Risk factors

However, UTIs are recurrently encountered in healthcare amenities, the high infection rates could be associated with some risk factors. The gender, females are usually at high risk; it is expected that 40–60% of females will get UTIs at least once in their life, and half of them will suffer from recurrency within 1 year [9, 11, 12]. In males, the incidence of UTIs is lower than in females (10–15%), and even lower in circumcised males [10].

Females are at a higher risk of UTIs for various reasons; first of all, their shorter urethra eases the spread of bacteria to the bladder establishing infection [15]. Additionally, anatomical differences between males and females make self-infection from perineal flora more likely in females [9]. Hormonal changes during menopause, which reduce estrogen levels, also increase the risk of infection by making urogenital skin thinner and reducing the presence of protective Lactobacilli, as the lactic acid production by Lactobacilli renders the vaginal pH more acidic that does not encourage the growth of invading bacteria conferring a protective barrier against pathogenic infections [16]. Furthermore, the immunocompromised individuals including geriatrics and pregnant women are at high risk [17, 18, 19, 20]. In diabetic patients, nephropathy, glycosuria, and reduced immunity contribute to the higher incidence of complicated UTIs [3, 21, 22, 23]. Other factors that increase the risk of UTIs comprise anatomical abnormalities of the urinary tract, kidney stones, and the use of physical interventions such as spermicides, contraceptive diaphragms, intrauterine devices, catheters, and frequent pelvic examinations [10, 14].

Advertisement

3. Bacterial and fungal etiology of UTIs

The bacterial etiology of UTIs involves a variety of Gram-positive and -negative bacteria as well as the most common fungal infections by Candida spp., mainly C. albicans (Figure 1) [2]. Typically, the infections are mostly originated from the normal flora of the urogenital system, vaginal, and rectum besides the intestinal microbiota serving as the main reservoir of infections [4, 9]. Escherichia coli is the most frequently identified urinary tract pathogen, responsible for 65% of complicated UTIs and 75% of uncomplicated UTIs [24]. Klebsiella pneumoniae is the second most frequent cause of UTIs, accounting for 6–8% of cases, while C. albicans and Enterococcus faecalis are significant causes of complicated UTIs, causing 7% and 11% of UTIs, respectively [14]. Other less commonly identified causative agents include Staphylococcus saprophyticus, Staphylococcus aureus, Staphylococcus epidermidis, group B Streptococcus, Proteus mirabilis, Acinetobacter baumannii, and Pseudomonas aeruginosa [14, 25].

Figure 1.

The most common uropathogens (adopted from Lila et al. [2]). UTIs are caused by a wide range of Gram-positive and -negative bacterial pathogens and fungal pathogens mainly Candida spp.

Advertisement

4. Pathogenesis of UTIs

The bacterial ability to breach the urethral sphincter muscle, the natural barrier against pathogens, initiates pathogenesis employing bacterial fimbriae and adhesin to adhere to the urethral epithelium [26, 27]. Then, bacteria ascend the urethra and colonize the urinary bladder, where they express numerous virulence factors that promote necrosis of tissues and facilitate invasion, resulting in cystitis [4, 14, 28]. UTIs symptoms extend to include fever, suprapubic pain, lower abdominal pain, blisters, and ulcers in the urogenital area besides bacteriuria, dysuria, urgency, urinary frequency, pyuria, itching, and burning sensation during urination [29, 30].

Advertisement

5. Catheter-associated urinary tract infections (CAUTIs)

CAUTIs are the most frequent hospital-acquired infections and account for nearly 40% of all infections [3, 21]. Urinary catheters are foreign bodies that induce local mechanical stress, causing various inflammatory responses such as mucosal lesions edema, and exfoliation [21]. Insufficient use of aseptic techniques while inserting a catheter can cause contamination, which in turn can result in CAUTIs. The probability of developing UTIs is notably high when catheterization is prolonged (beyond 7 days) because the surface of urinary catheters provides an optimal environment for bacterial growth and attachment [21, 31]. Additionally, the deposited fibrinogen lubricates the catheter surface and serves as a nutrient source providing an ideal niche for bacterial attachment [23].

Advertisement

6. Biofilm formation

Biofilm formation constitutes the cornerstone in the UTIs pathogenesis playing the main role in CAUTIs [32, 33, 34]. Moreover, the formation of biofilms is regarded as a crucial factor contributing to the frequent recurrence of UTIs. In Refs. [2332], and antimicrobial resistance [34, 35, 36, 37]. These biofilms are anchored in the place by an extracellular polymer matrix that is secreted by the bacteria themselves, which constitute an obstacle against antibiotics to attack bacteria [2, 26, 38]. The behavior of bacteria in biofilms is different from that of planktonic bacteria, they prioritize fortifying their establishment plan over motility and metabolic activities to conserve nutrients and energy [26, 39, 40]. They upregulate extracellular toxins to cause maximum tissue damage, releasing nutrients and cementing the biofilm in place [41, 42]. The biofilm sheds daughter planktonic cells that persistently disseminate the infection and create new biofilms. These biofilms are difficult to eradicate and can lead to chronic and recurrent infections [13, 26].

Advertisement

7. Objectives of UTIs book

UTIs are a common health issue that affects millions of people around the world every year, resulting in discomfort and pain that have a significant impact on a person’s quality of life, and if left untreated, can lead to more serious complications. This book aims to provide a comprehensive guide to understanding UTIs, their causes, symptoms, and treatment options. Through this book, readers will gain a better understanding of the risk factors associated with UTIs, as well as ways to prevent and manage them. The book will cover both conventional and alternative treatments, as well as lifestyle changes that can help prevent UTIs from occurring. In addition to providing valuable information for those who have already experienced UTIs, this book will also serve as a valuable resource for healthcare professionals who treat patients with UTIs. By presenting the latest research and evidence-based recommendations, this book will help healthcare providers make informed decisions about diagnosis and treatment.

References

  1. 1. Saint S, Kowalski CP, Kaufman SR, Hofer TP, Kauffman CA, Olmsted RN, et al. Preventing hospital-acquired urinary tract infection in the United States: A national study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(2):243-250. DOI: 10.1086/524662
  2. 2. Lila ASA, Rajab AA, Abdallah MH, Rizvi SMD, Moin A, Khafagy E-S, et al. Biofilm lifestyle in recurrent urinary tract infections. Life. 2023;13(1):148
  3. 3. Oumer Y, Regasa Dadi B, Seid M, Biresaw G, Manilal A. Catheter-associated urinary tract infection: Incidence, associated factors and drug resistance patterns of bacterial isolates in southern Ethiopia. Infectious Drug Resistances. 2021;14:2883-2894. DOI: 10.2147/IDR.S311229
  4. 4. McLellan LK, Hunstad DA. Urinary tract infection: Pathogenesis and outlook. Trends in Molecular Medicine. 2016;22(11):946-957. DOI: 10.1016/j.molmed.2016.09.003
  5. 5. Medina-Polo J, Naber KG, Bjerklund Johansen TE. Healthcare-associated urinary tract infections in urology. GMS Infectious Diseases. 2021;9:Doc05. DOI: 10.3205/id000074
  6. 6. Ronald A. The etiology of urinary tract infection: Traditional and emerging pathogens. The American Journal of Medicine. 2002;113(Suppl 1A):14S-19S. DOI: 10.1016/s0002-9343(02)01055-0
  7. 7. Sabih A, Leslie SW. Complicated Urinary Tract Infections. Treasure Island, FL: StatPearls; 2022
  8. 8. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Therapeutic Advances in Urology. 2019;11:1756287219832172. DOI: 10.1177/1756287219832172
  9. 9. Minardi D, d’Anzeo G, Cantoro D, Conti A, Muzzonigro G. Urinary tract infections in women: Etiology and treatment options. International Journal of General Medicine. 2011;4:333-343. DOI: 10.2147/IJGM.S11767
  10. 10. Bono MJ, Leslie SW, Reygaert WC. Urinary Tract Infection. Treasure Island, FL: StatPearls; 2022
  11. 11. Suskind AM, Saigal CS, Hanley JM, Lai J, Setodji CM, Clemens JQ , et al. Incidence and management of uncomplicated recurrent urinary tract infections in a national sample of women in the United States. Urology. 2016;90:50-55. DOI: 10.1016/j.urology.2015.11.051
  12. 12. Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Canadian Urological Association Journal. 2011;5(5):316-322. DOI: 10.5489/cuaj.11214
  13. 13. Vestby LK, Grønseth T, Simm R, Nesse LL. Bacterial biofilm and its role in the pathogenesis of disease. Antibiotics (Basel). 3 Feb 2020;9(2):59. DOI: 10.3390/antibiotics9020059. PMID: 32028684; PMCID: PMC7167820
  14. 14. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nature Reviews. Microbiology. 2015;13(5):269-284. DOI: 10.1038/nrmicro3432
  15. 15. Barber AE, Norton JP, Wiles TJ, Mulvey MA. Strengths and limitations of model systems for the study of urinary tract infections and related pathologies. Microbiology and Molecular Biology Reviews. 2016;80(2):351-367. DOI: 10.1128/MMBR.00067-15
  16. 16. Storme O, Tiran Saucedo J, Garcia-Mora A, Dehesa-Davila M, Naber KG. Risk factors and predisposing conditions for urinary tract infection. Therapeutic Advances in Urology. 2019;11:1756287218814382. DOI: 10.1177/1756287218814382
  17. 17. Glover M, Moreira CG, Sperandio V, Zimmern P. Recurrent urinary tract infections in healthy and nonpregnant women. Urological Science. 2014;25(1):1-8. DOI: 10.1016/j.urols.2013.11.007
  18. 18. Giannakopoulos X, Sakkas H, Ragos V, Tsiambas E, Bozidis P, et al. Impact of enterococcal urinary tract infections in immunocompromised - neoplastic patients. Journal of BUON. 2019;24(5):1768-1775
  19. 19. Askoura M, Abbas HA, Al Sadoun H, Abdulaal WH, Abu Lila AS, Almansour K, et al. Elevated levels of IL-33, IL-17 and IL-25 indicate the progression from chronicity to hepatocellular carcinoma in hepatitis C virus patients. Pathogens. 2022;11(1):57. DOI: 10.3390/pathogens11010057
  20. 20. Hegazy WAH, Henaway M. Hepatitis C virus pathogenesis: Serum IL-33 level indicates liver damage. African Journal of Microbiology Research. 2015;9(20):1386-1393. DOI: 10.5897/AJMR2015.7496
  21. 21. Venkataraman R, Yadav U. Catheter-associated urinary tract infection: An overview. Journal of Basic and Clinical Physiology and Pharmacology. 29 Aug 2022;34(1):5-10. DOI: 10.1515/jbcpp-2022-0152. PMID: 36036578
  22. 22. Hegazy WAH, Rajab AAH, Abu Lila AS, Abbas HA. Anti-diabetics and antimicrobials: Harmony of mutual interplay. World Journal of Diabetes. 2021;12(11):1832-1855. DOI: 10.4239/wjd.v12.i11.1832
  23. 23. Niveditha S, Pramodhini S, Umadevi S, Kumar S, Stephen S. The isolation and the biofilm formation of uropathogens in the patients with catheter associated urinary tract infections (UTIs). Journal of Clinical and Diagnostic Research. 2012;6(9):1478-1482. DOI: 10.7860/JCDR/2012/4367.2537
  24. 24. Sarowska J, Futoma-Koloch B, Jama-Kmiecik A, Frej-Madrzak M, Ksiazczyk M, Bugla-Ploskonska G, et al. Virulence factors, prevalence and potential transmission of extraintestinal pathogenic Escherichia coli isolated from different sources: Recent reports. Gut Pathogens. 2019;11:10. DOI: 10.1186/s13099-019-0290-0
  25. 25. Pinault L, Chabriere E, Raoult D, Fenollar F. Direct identification of pathogens in urine by use of a specific matrix-assisted laser desorption ionization-time of flight spectrum database. Journal of Clinical Microbiology. 28 Mar 2019;57(4):e01678-18. DOI: 10.1128/JCM.01678-18. PMID: 30700506; PMCID: PMC6440795
  26. 26. Delcaru C, Alexandru I, Podgoreanu P, Grosu M, Stavropoulos E, Chifiriuc MC, et al. Microbial biofilms in urinary tract infections and prostatitis: Etiology, pathogenicity, and combating strategies. Pathogens. 30 Nov 2016;5(4):65. DOI: 10.3390/pathogens5040065. PMID: 27916925; PMCID: PMC5198165
  27. 27. Askoura M, Almalki AJ, Lila ASA, Almansour K, Alshammari F, Khafagy E-S, et al. Alteration of salmonella enterica virulence and host pathogenesis through targeting sdiA by using the CRISPR-Cas9 system. Microorganisms. 2021;9(12):2564. DOI: 10.3390/microorganisms9122564
  28. 28. Flores-Mireles AL, Walker JN, Bauman TM, Potretzke AM, et al. Fibrinogen release and deposition on urinary catheters placed during urological procedures. The Journal of Urology. 2016;196(2):416-421. DOI: 10.1016/j.juro.2016.01.100
  29. 29. Cortes-Penfield NW, Trautner BW, Jump RLP. Urinary tract infection and asymptomatic bacteriuria in older adults. Infectious Disease Clinics of North America. 2017;31(4):673-688. DOI: 10.1016/j.idc.2017.07.002
  30. 30. Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. American Journal of Obstetrics and Gynecology. 2018;219(1):40-51. DOI: 10.1016/j.ajog.2017.12.231
  31. 31. Guiton PS, Hannan TJ, Ford B, Caparon MG, Hultgren SJ. Enterococcus faecalis overcomes foreign body-mediated inflammation to establish urinary tract infections. Infection and Immunity. 2013;81(1):329-339. DOI: 10.1128/IAI.00856-12
  32. 32. Rishpana MS, Kabbin JS. Candiduria in catheter associated urinary tract infection with special reference to biofilm production. Journal of Clinical and Diagnostic Research. 2015;9(10):DC11. DOI: 10.7860/JCDR/2015/13910.6690
  33. 33. Balestrino D, Souweine B, Charbonnel N, Lautrette A, Aumeran C, Traore O, et al. Eradication of microorganisms embedded in biofilm by an ethanol-based catheter lock solution. Nephrology, Dialysis, Transplantation. 2009;24(10):3204-3209. DOI: 10.1093/ndt/gfp187
  34. 34. Cavalu S, Elbaramawi SS, Eissa AG, Radwan MF, et al. Characterization of the anti-biofilm and anti-quorum sensing activities of the β-Adrenoreceptor antagonist atenolol against gram-negative bacterial pathogens. International Journal of Molecular Sciences. 2022;23(21):13088. DOI: 10.3390/ijms232113088
  35. 35. Thabit AK, Eljaaly K, Zawawi A, Ibrahim TS, Eissa AG, Elbaramawi SS, et al. Muting bacterial communication: Evaluation of Prazosin anti-quorum sensing activities against gram-negative bacteria Pseudomonas aeruginosa, Proteus mirabilis, and Serratia marcescens. Biology (Basel). 2022;11(9). DOI: 10.3390/biology11091349
  36. 36. Khayyat AN, Abbas HA, Khayat MT, Shaldam MA, Askoura M, Asfour HZ, et al. Secnidazole is a promising imidazole mitigator of Serratia marcescens virulence. Microorganisms. 2021;9(11):2333. DOI: 10.3390/microorganisms9112333
  37. 37. Almalki AJ, Ibrahim TS, Elhady SS, Hegazy WAH, Darwish KM. Computational and biological evaluation of β-Adrenoreceptor blockers as promising bacterial anti-virulence agents. Pharmaceuticals. 2022;15(2):110. DOI: 10.3390/ph15020110
  38. 38. Elfaky MA, Thabit AK, Eljaaly K, Zawawi A, Abdelkhalek AS, Almalki AJ, et al. Controlling of bacterial virulence: Evaluation of anti-virulence activities of Prazosin against Salmonella enterica. Antibiotics (Basel). 9 Nov 2022;11(11):1585. DOI: 10.3390/antibiotics11111585. PMID: 36358239; PMCID: PMC9686722
  39. 39. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clinical Microbiology Reviews. 2002;15(2):167-193. DOI: 10.1128/CMR.15.2.167-193.2002
  40. 40. Khayyat AN, Abbas HA, Mohamed MFA, Asfour HZ, Khayat MT, Ibrahim TS, et al. Not only antimicrobial: Metronidazole mitigates the virulence of Proteus mirabilis isolated from macerated diabetic foot ulcer. Applied Sciences. 2021;11(15):6847. DOI: 10.3390/app11156847
  41. 41. Solano C, Echeverz M, Lasa I. Biofilm dispersion and quorum sensing. Current Opinion in Microbiology. 2014;18:96-104. DOI: 10.1016/j.mib.2014.02.008
  42. 42. Hegazy WAH, Salem IM, Alotaibi HF, Khafagy E-S, Ibrahim D. Terazosin interferes with quorum sensing and type three secretion system and diminishes the bacterial espionage to mitigate the Salmonella typhimurium pathogenesis. Antibiotics. 2022;11:465. DOI: 10.3390/antibiotics11040465

Written By

Wael Hegazy

Submitted: 26 April 2023 Published: 02 November 2023